A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol

Yun Chen¹, Zhengfei Zhu¹, Weixin Zhao¹, Ling Li¹, Jinjun Ye², Chao Yang Wu³, Huarong Tang³, Qin Lin⁴, Jiancheng Li⁵, Yi Xia⁶, Yunhai Li⁶, Jialiang Zhou⁷ and Kuaile Zhao¹*

Abstract

Background: Concurrent chemoradiotherapy is a standard modality for locally advanced esophageal squamous cell carcinoma (ESCC) patients. Cisplatin combined with 5-fluorouracil continuous infusion (PF) remains the standard concurrent chemotherapy regimen. However, radiotherapy concurrent with PF showed a high incidence of severe side effects. Paclitaxel showed a promising radiosensitivity enhancement in the treatment of esophageal carcinoma in both vitro and vivo studies. The ESO-Shanghai 1 trial examines the hypothesis that paclitaxel plus 5-fluorouracil (TF) concurrent with radiotherapy has better overall survival and lower toxicity for patients with local advanced ESCC.

Method: Four hundred thirty-six ESCC patients presenting with stage IIa to IVa will be enrolled in a prospective multicenter randomized phase 3 study. Patients will be randomized to either concurrent chemoradiotherapy with PF (cisplatin 25 mg/m²/d, d1–3, plus 5-fluorouracil 1800 mg/m², continuous infusion for 72 h) once every 4 weeks for 2 cycles followed by consolidation chemotherapy for 2 cycles or concurrent chemoradiotherapy with weekly TF (5-fluorouracil 300 mg/m², continuous infusion for 96 h plus paclitaxel 50 mg/m², d1) for 5 weeks followed by consolidation chemotherapy (5-fluorouracil 1800 mg/m², continuous infusion for 72 h, plus paclitaxel 175 mg/m² d1) once every 4 weeks for 2 cycles. The radiotherapy dose is 61.2 Gy delivered in 34 fractions to the primary tumor including lymph nodes. The primary end-point is the 3-yr overall survival analyzed by intention to treat. The secondary endpoints are disease progression-free survival, local progression-free survival, and number and grade of participants with adverse events.

Discussion: The aim of this phase 3 study is to determine whether the TF regimen could replace the standard PF regimen for inoperable ESCC patients. An overall survival benefit of 12% at 3 years should be expected in the TF group to achieve this goal.

Trial registration: ClinicalTrials.gov Identifier: NCT01591135. Registered 18 April 2012.

Keywords: Esophageal squamous cell carcinoma, Concurrent chemoradiotherapy, Paclitaxel, Cisplatin, 5-fluorouracil

* Correspondence: kuaile_z@sina.com
¹Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 DongAn Road, Shanghai 200032, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Concurrent chemoradiotherapy (CCR) is a standard modality for locally advanced esophageal squamous cell carcinoma (ESCC) patients. Cisplatin combined with 5-fluorouracil continuous infusion (PF) remains the standard concurrent chemotherapy regimen [1]. Identifying a new combination of drugs with superior efficacy but less toxicity is one of the important solutions to enhance radiosensitivity to improve the survival of this disease. Recently, both experimental and clinical research has demonstrated good efficacy and radiosensitivity of paclitaxel (PTX) in the treatment of esophageal carcinoma (EC). As a result, many researchers and oncologists have shown a great interest in the role of this promising agent played in CCR in EC.

PTX is one of the effective agents in the treatment of EC
Early in 1994, the co-work at the University of Texas M.D. Anderson Cancer Center (MDACC) and Memorial Sloan-Kettering Cancer Center proved that PTX is one of the effective agents in the treatment of EC, with the response rate of 34% in adenocarcinoma and 28% in squamous cell carcinoma [2, 3]. Thereafter, many institutions have conducted numerous studies using PTX combined with other agents, among which PTX plus cisplatin (TP) and PTX plus cisplatin plus 5-fluorouracil (TPF) were the most common combinations used in the treatment of advanced EC, with a response rate of 41% to 55% (Table 1).

Preclinical research shows the radiosensitivy enhancement of PTX
PTX has two main antitumor mechanisms: ① blocking the tumor at the G2/M phase of the cell cycle so as to inhibit the cell mitosis and proliferation; ② inducing the apoptosis of tumor cells. The inhibition of mitosis occurs quickly and disappears soon after, while apoptosis occurs late and last for a long time. Mitosis inhibition appears 2 h after the intravenous infusion of PTX and then accumulates over time. It reaches its peak after 8 to 12 h and is reduced gradually, and then it disappears in 1 to 2 days. By contrast, apoptosis occurs 6 to 9 h after the drug administration and gradually reaches a peak in 12 to 24 h that lasts for several hours to 2 days before gradually being reduced to the baseline after 2 to 3 days. Inhibition of mitosis does not cause the death of cells, but apoptosis does [4, 5]. Based on these mechanisms, researchers have tried to optimize the regimen of CCR using PTX to exaggerate the radiosensitivity enhancement.

Regarding in vitro experiments, most studies have found that PTX has the supra-additive action with the enhancement ratio of 1.1 to 3.4 [4]. However, some studies have shown only additive action or even subadditive action of PTX. An explanation for the different outcomes may be the different cell lines, proliferation status, drug concentration, or timing of administration of drug and irradiation chosen in different studies [6]. The studies showing a high ratio of radiosensitivity enhancement of PTX mostly used cell lines with high proliferation potential, drug concentrations of 5 to 100 nmol/L, cell lines that were cultured for more than 24 h, and irradiation when most cells reached the G2/M phase of the cell cycle after the administration of PTX. As a result, these conditions would help radiation killed the cells so as to improve the effect.

Regarding in vivo experiments, PTX also showed a good radiosensitivity enhancement with a ratio of 1.2 to 2.0. However, the highest radiosensitivity ratio did not occur at the time when most cells were arrested at the G2/M phase after irradiation as in vitro studies, but it occurred 3 days after the administration of PTX to the irradiated tumor cells. The radiosensitivity ratio is then decreased 4 days after the administration of PTX. The results of the in vitro and in vivo studies were obviously different and may demonstrate unknown mechanisms other than mitosis inhibition of PTX. The percentage of hypoxia cells in tumor cells was 32% before drug administration and decreased to 15%, 4%, 2% and 1% after 9, 24, 48, and 72 h of PTX administration, respectively. The tendency exactly matched the change in the radiosensitivity ratio. Thus, the reoxygenation of hypoxia cells induced by apoptosis play a more important role than mitosis inhibition in the mechanism of radiosensitivity enhancement of PTX in treating solid tumors [7, 8].

Table 1 Efficacy of PTX-based chemotherapy for advanced esophageal cancer

| Authors          | Cases (SC/AC/other) | Chemotherapy                              | Efficacy |
|------------------|---------------------|-------------------------------------------|----------|
| van der Gaast et al. [20] | 31(NA/NA)          | PTX 100–160 mg/m² iv3h, d1; DDP 60 mg/m², d1, q2w | 55% 53% 60% |
| Kelsen, et al. [21]  | 37(27/10)           | PTX 200 mg/m², cic24h, d1; DDP 75 mg/m², d1, q3w | 49% 60% 44% |
| Polee, et al. [22]  | 51(16/31/4)         | PTX 180 mg/m², iv3h, d1; DDP 60 mg/m², d1, q2w | 43% 39% 44% |
| Huang, et al. [23]  | 30/30/0             | PTX 175 mg/m², iv3h, d1; DDP 40 mg/m², d2, 3, q3w | 59% 59% – |
| Ilson, et al. [24]  | 61(31/30)           | PTX 175 mg/m² iv3h, d1; DDP 20 mg/m², 5d; S-FU 1 g/m²/d, 5d; q3w | 48% 50% (CR 20%) 46%(CR 3%) |
| Lin, et al. [25]   | 41(41/0)            | PTX 35 mg/m², d1, 4, 8, 11, DDP 20 mg/m², d2, 5, 9, 12; S-FU 2 g/m², q3w | 39% 39% – |

Abbreviations: SC squamous cell carcinoma, AC adenocarcinoma, PTX paclitaxel, S-FU 5-fluorouracil, DDP cisplatin, CR complete response
Consequently, PTX played a radiosensitivity enhancement role in the laboratory studies. However, only by using certain cell lines, an adequate PTX concentration and the appropriate irradiation timing could we obtain the expected results. Otherwise, PTX may play no role in radiosensitivity enhancement and may even counteract the radiation effects and decrease the therapeutic effects. Unfortunately, to date, we have found no study that has focused on the radiosensitivity enhancement role of PTX played in EC cell lines.

**Phase 2 clinical trials of EC patients treated with PTX-based CCR**

Neoadjuvant CCR followed by surgery is the standard treatment for operable EC patients, especially in western countries. Previous randomized studies have shown that the pathologic complete response (pCR) and 3-yr overall survival (OS) of PF concurrent with 40 Gy of radiotherapy was 15–40% and 26–32%, respectively [9]. Since PTX had considerable efficiency and radiosensitivity enhancement in the preclinical studies, researchers conducted many clinical studies with different PTX-based concurrent regimens to find an optimal one to replace the PF regimen. In 1997, Massachusetts General Hospital and Fox Chase Cancer Center separately reported a phase 1 study of neoadjuvant CCR with PTX-based regimen followed by surgery in EC patients [10, 11]. The results confirmed that the TPF regimen was tolerable and efficient with a pCR rate of up to 39% in operable EC patients and 50% in patients who could complete all the chemotherapy cycles. Over the past decade, researchers from different countries and institutions have performed many phase 2 studies based on this phase 1 study. Although there were some differences in the dose and combination of PTX among the different studies, the pCR rates of the PTX-based regimen were 16–67% higher than the classical PF regimen (Table 2).

**Case-control study of PTX-based regimen versus PF regimen in CCR in EC patients**

Based on the preferable results of phase 2 studies, PTX was widely used in clinical practice. However, there was no prospective randomized phase 3 study comparing the PTX-based regimen with the PF regimen in CCR in EC patients. Recently, several retrospective non-randomized case-control studies compared the toxicities between these two regimens. Unfortunately, the outcome was disappointing. In 2000, the Cleveland Clinic Foundation initiated a phase 2 study of neoadjuvant CCR with the PTX-based regimen followed by surgery in EC patients, and historically compared the study with another conducted at the same institution using the PF regimen instead [12]. The results showed that, although the pCR rate and 3-yr OS in both studies were similar, the incidence rate of severe leukocytopenia and the hospital stay time in the PTX-based group were twice than that in the PF group. Because these two studies were performed at the same institute using similar inclusion criteria, and had the same radiotherapy prescriptions and comparable clinical characteristics such as stages and pathologies, researchers decided to conduct a case-control study to compare the results.

**Table 2** Phase 2 studies of PTX-based preoperative neoadjuvant chemoradiotherapy for EC patients

| Authors          | Cases (SC/AC/other) | Chemotherapy                                                                 | Radiation dose (Gy) | Median survival (months) | pCR Total | SC | AC |
|------------------|---------------------|-------------------------------------------------------------------------------|---------------------|--------------------------|-----------|----|----|
| Safran, et al.   | 41 (12/29)          | PTX 60 mg/m²² 3 h; DDP 25 mg/m²; d1, 8, 15, 22                               | 39.6                | 15                       | 29%       | 42%| 24%|
| Bains, et al.    | 41 (16/25)          | Induction, DDP 75 mg/m²²; PTX 175 mg/m²²; W 1, 4; Concurrent, DDP 30 mg/m²²/w; PTX 30–80 mg/m²²/w, 96 h civ w 7–12 | 50.4                | –                        | 22%       | 31%| 16%|
| Urba, et al.     | 69 (10/57/2)        | DDP 75 mg/m²² d1; PTX 60 mg/m²² d1, 8, 15, 22                              | 45                  | 24                       | 19%       | –  | –  |
| Van Meerten, et al. | 54 (12/41/1)    | PTX 50 mg/m²², d1, 8, 15, 22, 29; CBP AUC = 2, d1, 8, 15, 22, 29          | 41.4                | –                        | 25%       | –  | –  |
| Meluch, et al.   | 129 (35/91/3)       | PTX 200 mg/m²², 1 h, d1, 22; CBP AUC = 4, d1, 22; S-FU 225 mg/m²²/d, civ, d1–42 | 45                  | 22                       | 38%       | 53%| 37%|
| Lin, et al.      | 97 (92/5)           | PTX 35 mg/m²², 1 h, d1, d3; DDP 15 mg/m²² d2, d5                            | 40                  | 29                       | 25%       | –  | –  |
| Jatoi, et al.    | 54 ( interpolate)   | PTX 200 mg/m²², 1 h, d1, 22; CBP AUC = 4, d1, 22; S-FU 225 mg/m²²/d, civ, d1–42 | 45                  | 21.2                     | 35%       | –  | –  |

Abbreviations: SC squamous cell carcinoma, AC adenocarcinoma, pCR pathologic complete response, PTX paclitaxel, S-FU 5-fluorouracil, DDP cisplatin, CBP carboplatin, AUC area under the curve
the results were partially reliable despite the limitations of comparative historical research. Certainly, some researchers had different opinions and queried the design of the study with non-randomized, insufficient cases, no standard treatment, and unreasonable split course of preoperative chemoradiotherapy [13]. Therefore, this negative result did not stop the researchers from further investigating PTX in CCR for the treatment of EC. However, many retrospective studies showed no significant difference in both the efficacy and side effects between the two regimens (Table 3).

In 2008, the Radiation Therapy Oncology Group (RTOG) reported a phase 2 randomized control study called RTOG 0113, which compared two PTX-based regimens used in induction chemotherapy followed by CCR to determine which regimen could achieve a better 1-yr OS and surpassed the historical result of RTOG 9405 [14, 15]. In this study, patients were randomly assigned to two arms. The patients in Arm A received induction chemotherapy with 5-FU 700 mg/m^2, d1–5, DDP 15 mg/m^2, d1–5, and PTX 200 mg/m^2, civ 24 h, q4w * 2 and then CCR with 5-FU 300 mg/m^2, civ 96 h, and PTX 50 mg/m^2, d1, qw * 5. The patients in Arm B received induction chemotherapy with PTX 175 mg/m^2, d1, and DDP 75 mg/m^2, d1, q3w * 2 and then CCR with DDP 30 mg/m^2, and PTX 60 mg/m^2, civ 96 h, qw * 5. Both arms received 50.4 Gy of radiation. Seventy-two patients were assessable in the study, 37 patients in arm A and 35 patients in arm B. In arm A, the median survival time was 28.7 months, the 1-yr and 2-yr OS rates were 76% and 56%, respectively, the incidence rates of grade 3 and 4 toxicities were 54% and 27%, respectively, and treatment-related death was 3%. In arm B, the median survival time was 14.9 months, the 1-yr and 2-yr OS rates were 69% and 37%, respectively, the incidence rates of grade 3 and 4 toxicities were 43% and 40%, respectively, and treatment-related death was 6%. Although the 1-yr OS in Arm A was higher than that in RTOG 9405 (76% vs. 66%), it did not meet the 1-yr survival rate goal.

**Rationale for the trial**

Based on this evidence, we designed this phase 3 study to assess whether the PTX-based regimen was better than the PF regimen in CCR. The CCR regimen used in the control group referred to the PF regimen used in RTOG 8501 with some modifications, while the CCR regimen used in the experimental group referred to the TF regimen designed by MDACC in RTOG 0113.

**Methods/design**

**Design**

The ESO-Shanghai 1 trial is a prospective multicenter randomized phase 3 study in which patients are randomized to either CCR with the PF regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles or to CCR with a weekly TF regimen for 5 weeks followed by consolidation chemotherapy for 2 cycles (Fig. 1).

**Objectives**

**Primary endpoints**

- 3-yr OS
  - Defined in the intent-to-treat population.
  - Time from the start of study treatment (Day 1) to death from any cause.

**Secondary endpoints**

| Institution/Study Type | Cases | CT   | RT | pCR (%) | 3-yr OS (%) | ≥3 Side effect |
|------------------------|-------|------|----|---------|-------------|---------------|
|                        |       | Total| SC | AC      |             |               |
| Cleveland Clinic Foundation [12]/prospective, non-randomized | 72 PF | 45 Gy, 1.5 Gy/FX, BID (split course) or 24 Gy postoperative | 27 | 36 | 22 | 36 | Vomiting (1%), mucositis (18%), leucopenia (43%), thrombocytopenia (10%), nephrotoxicity (8%), unplanned hospitalization (25%) |
|                        | 40 TP | 23 | 50 | 8 | 30 | Mucositis (13%), leucopenia (95%), neuropathy (13%), unplanned hospitalization (48%) |
| Duke University [9]/retrospective | 57 PF | 45–50.4 Gy, 1.8–2.0 Gy/FX | 40 | – | – | 37 | 24% |
|                        | 52 TPF | 39 | – | – | 37 | 34% |
| Massachusetts General Hospital [33]/retrospective | 81 PF | CTV 45 Gy/25FX, GTV 58.5 Gy/25FX (13.5 Gy, 1.5 Gy/FX concomitant boost during the first and second cycles of CT) | 46 | – | – | 39 | 79% |
|                        | 83 TPF | 37 | – | – | 42 | 80% |

**Abbreviations:** CT chemotherapy, RT radiotherapy, SC squamous cell carcinoma, AC adenocarcinoma, pCR pathologic complete response, OS overall survival, PF cisplatin plus 5-fluorouracil, TP paclitaxel plus cisplatin, TPF paclitaxel plus cisplatin plus 5-fluorouracil
- Disease progression-free survival
  Defined in the intent-to-treat population.
  Time from Day 1 to the first event of local failure, metastatic recurrence, progression or death.
  Progression will be examined by computed tomography (CT), esophageal radiography and/or upper endoscopy
- Local progression-free survival
  Defined in the intent-to-treat population.
  Time from Day 1 to the first event of local failure.
  Local progression will be examined by CT, esophageal radiography and/or upper endoscopy, and is defined as local progression within the irradiated field
- Number and grade of participants with Adverse Events
  Adverse events will be graded according to the Common Terminology Criteria for Adverse Events version 4.0 [16]

To achieve these objectives, 436 patients will be recruited and randomly allocated in a 1:1 to the two arms by a central randomization center (Fudan University Shanghai Cancer Center, Shanghai, China) stratified by investigator center. SAS will be used to generate a random permutation sequence and produce patient randomization numbers. The data center will register the enrollment, assign a unique identification number to every participant, and reply to the respective investigators. Written informed consent will be obtained from all patients prior to participation in the trial. Patient recruitment will occur at 7 trial centers in China. All participating centers are highly experienced in esophageal radiation oncology, with at least 100 cases performed per year in each center.

**Patient selection**

**Initial diagnosis**

1. Endoscopic assessment with biopsy
2. CT scan of chest and ultrasound of abdomen and neck are required (CT/MRIs are acceptable)
3. Fine needle aspirations are required for all superficial lymph node metastases (e.g. supraclavicular lymph node metastases)
4. Full blood count, renal function, and liver function test (bilirubin, AST/ALT, alkaline phosphatase, total protein, albumin, globulin) within 14 days prior to enrolment.
5. Physical examination and history to include height and weight

**Inclusion criteria**

Eligible patients must meet all of the following criteria:

1. Joined the study voluntarily and signed informed consent form;
2. Age 18–75 years; both genders
3. Esophageal squamous cell carcinoma confirmed by pathology. No radiotherapy, chemotherapy or other treatments prior to enrollment
4. Local advanced esophageal squamous cell carcinoma (T2N0M0-TxNxM1a, AJCC 2002)
5. Use of an effective contraceptive for adults to prevent pregnancy.
6. No severe abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function. No immunodeficiency.
7. WBC $\geq 3 \times 10^9/L$, Hemoglobin $\geq 9$ g/dL, Neutrophils $\geq 1.5 \times 10^9/L$, Platelet count (Plt) $\geq 100 \times 10^9/L$, ALAT and ASAT $< 2.5 \times$ ULN, TBIL $< 1.5 \times$ ULN, Creatinine $< 1.5 \times$ULN.
8. ECOG 0–2.
9. Life expectancy of more than 3 months.

Exclusion criteria
Patients meeting any of the following criteria are not eligible for this trial:
1. Complete esophageal obstruction, deep esophageal ulcer, esophageal perforation, or hematemesis.
2. History of radiotherapy or chemotherapy for esophageal cancer.
3. History of surgery within 28 days before Day 1.
4. History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years).
5. Participation in other interventional clinical trials within 30 days.
6. Pregnant or breast-feeding women or fertile patients who refused to use contraceptives.
7. Drug addiction, alcoholism or AIDS.
8. Uncontrolled seizures or psychiatric disorders.
9. Patients with metastatic disease i.e. M1b according to AJCC 2002.
10. Any other condition which in the investigator's opinion would not make the patient a good candidate for the clinical trial.

Study treatment
The treatment scheme is shown in Fig. 2. Patients will receive CCR and consolidation chemotherapy. Radiotherapy will begin on Day 1, concurrent with the beginning of cycle 1 of chemotherapy.

Chemotherapy
Cisplatin plus 5-fluorouracil regimen (arm a)
The Arm A consists of 2 cycles of CCR and 2 cycles of consolidated chemotherapy post-radiotherapy. Each cycle of chemotherapy lasts 28 days (4 weeks). The drugs used in Arm A include cisplatin and 5-FU, which are applied intravenously according to the following scheme: 5-FU 1800 mg/m$^2$ civ 72 h day 1 and cisplatin 25 mg/m$^2$/d day 1–3 every 4 weeks.

Paclitaxel plus 5-fluorouracil regimen (arm B)
Arm B consists of 5 cycles of weekly CCR and 2 subsequent cycles of monthly consolidation chemotherapy post-radiotherapy. Each cycle lasts 7 days (1 week) in concurrent chemotherapy and 28 days (4 weeks) in consolidation chemotherapy. The drugs used in Arm B include PTX and 5-FU, which are applied intravenously according to the following scheme: 5-FU 300 mg/m$^2$ civ 96 h day 1 and PTX 50 mg/m$^2$/d day 1 every week in concurrent chemotherapy and 5-FU 1800 mg/m$^2$ civ 72 h day 1 and PTX 175 mg/m$^2$/d day every 4 weeks.

Chemotherapy interruption and dose modifications
Chemotherapy should be delayed in the conditions as follows:

Fig. 2 Treatment design of the ESO-Shanghai 1 trial. Patients in both Arms will receive concurrent chemoradiotherapy and consolidation chemotherapy. Radiotherapy will begin on Day 1, concurrent with the beginning of cycle 1 of chemotherapy. (Abbreviations: R, radiotherapy; PTX, paclitaxel; DDP (P), cisplatin; 5-FU (F), 5-fluorouracil; PF, cisplatin plus 5-fluorouracil; TF, paclitaxel plus 5-fluorouracil)
- ANC < 1.5 × 10^9/L
- Plt < 80 × 10^9/L
- ≥ Grade 3 nonhematological toxicities (nausea, vomiting and alopecia excluded)

Up to a 2-week delay of chemotherapy is allowed, or the chemotherapy will be terminated. The cycle should be administered only if the patient has recovered from toxicity (ANC ≥ 1.5 × 10^9/L, Plt ≥ 80 × 10^9/L and < Grade 3 non-hematological toxicities).

The chemotherapy dose should be modified according to the worst toxicity observed during the previous cycle. Chemotherapy should be administered with 25% dose reduction if ANC < 0.5 × 10^9/L, Plt < 25 × 10^9/L or ≥ Grade 3 non-hematological toxicities. In the case of both ANC < 0.5 × 10^9/L and Plt < 25 × 10^9/L, the chemotherapy should be terminated. Modifications up to 2 times are allowed, or chemotherapy will be terminated.

**Radiotherapy (both arms)**

Radiotherapy will be delivered in both arms with photons (6 MV) to a total dose of 61.2 Gy in 34 fractions. Patients will be treated 5 days per week at 1.8 Gy/d. Intensity modulated radiotherapy based on CT simulation planning system with 5-mm-thick scan slice throughout the entire neck and thorax is required. We will use involved-field irradiation in this study.

**Gross tumor volume (GTV)**

The GTV is defined as visible esophageal tumor and metastatic lymph nodes based on the imaging of endoscopic ultrasound, esophageal radiography or CT scan (whichever is larger). The criteria for metastatic lymph nodes are as follows: pathologic confirmation or short axis of ≥ 10 mm in the mediastinum or cervix, short axis of ≥ 5 mm in the tracheoesophageal groove, or histologically proven metastatic by puncture.

**Clinical target volume (CTV)**

The CTV is defined by the GTV grown manually by 30 mm in the superior-inferior direction for primary tumor and 0 mm for metastatic lymph nodes and 0 mm circumferentially.

**Planning target volume (PTV)**

The PTV is defined as a further 1-cm expansion added to the CTV in all directions. The field next to the spinal cord could be slightly changed to reduce the exposure of the spinal cord.

Tissue inhomogeneity correction is adopted in the planning system. The criteria of dose distribution are as follows: 95% of the PTV to receive ≥ 99% of the prescribed dose; < 2 cm³ of the PTV to receive ≥ 120% of the prescribed dose; < 1 cm³ of the PTV to receive ≥ 110% of the prescribed dose. The highest and lowest dose points inside the PTV should be recorded.

**Normal organ contouring and dose restrictions**

Normal organs, including the spinal cord, heart, right lung, and left lung, should be contoured on each slice of the planning CT with no planning margin. The spinal cord dose constraint cannot be exceeded for any reason. The heart contours should extend from the beginning of the right atrium and right ventricle (pulmonary artery trunk, ascending main aorta and superior vena cava were excluded) down to the apex of the heart. The lung volume is defined as the total lung minus PTV.

The priority order of consideration of normal organ dose restrictions is as follows:

1. Spinal cord: The highest dose point must be less than 45 Gy.
2. Lung: The volume of the lung (PTV excluded) receiving 20 Gy must be equal to or less than 30% of the total lung volume, and the mean lung dose must be equal to or less than 15 Gy at the same time.
3. Heart: The mean dose must be less than 40 Gy.

**Dose modifications**

It is strongly recommended that the normal organ dose constraints should not be exceeded. If any dose constraint needs to be exceeded to achieve adequate coverage of the PTV, the physician will decide whether the dose should be modified, or the patient should be excluded from the trial. The acceptable violations of dose modifications are as follows: 92–95% of the PTV to receive ≥ 99% of the prescribed dose; the normal organ dose restrictions (except the spinal cord) exceeding 5%–10%.

**Radiotherapy quality assurance**

Radiotherapy should be delayed until recovery from the toxicities to no more than grade 2 in the conditions as follows:

- WBC < 2.0 × 10^9/L or ANC < 1.0 × 10^9/L
- Plt < 50 × 10^9/L
- Grade 3 or higher non-hematological toxicity

Radiotherapy should be delayed until complete recovery if infection occurs with fever over 38.5 °C. Up to a 2-week delay of radiotherapy is allowed, or the radiotherapy will be terminated.

**Radiotherapy quality assurance**

The first 3 patients’ IMRT planning CT of each participating institution will be sent to Fudan University...
Shanghai Cancer Center for centrally quality assurance to demonstrate that the center complies with the specific study requirements for delineation, planning and dose distribution.

Statistical analysis
With a global alpha risk of 5% and 80% power, an accrual period of 48 months and a minimum follow-up of 36 months, and 6% patient loss, the inclusion of 436 patients (218 in each arm) will be necessary to demonstrate an improvement of 12% in overall survival at 3 years (from 30% in the PF arm to 42% in the TF arm, based upon the results of RTOG 8501 clinical trial and a phase 2 study) [1, 17]. The study will be terminated when 293 events occur. The median overall survival will be using the Kaplan-Meier method, and the log-rank test will be used to compare the overall survival among treatment arms.

Discussion
Although the RTOG 8501 showed a better OS in the CCR group with the PF regimen, the results revealed that the PF regimen was not an optimal regimen in CCR with only 30% patients surviving over 3 years and 44% and 20% patients developing severe and life-threatening side effects, respectively [1, 18]. In 2001, MDACC designed a new regimen with continuous infusion of 5-fluorouracil and weekly PTX combined with radiotherapy in the treatment of EC patients [19]. The results showed that this new regimen was well tolerated, with only one patient with grade 2 nausea and vomiting who had a delay of therapy. According to these lines of evidence, we initiated this prospective multicenter randomized phase 3 trial. The aim of this phase 3 trial is to determine whether the TF regimen could replace the standard PF regimen for inoperable ESCC patients. An OS benefit of 12% at 3 years should be expected in the TF group to achieve this goal. There are some limitations in this phase 3 trial. First, we did not stratify the patients according to the status of lymph node metastasis. Since this trial is randomized and the sample size is large enough, the influence of this limitation may be reduced. Second, we used the data of the results of RTOG 8501, which was conducted nearly 30 years ago, to estimate the 3-yr OS in the PF group and calculate the sample size. Because of the improvement in radiotherapy technology, the 3-yr OS of the control group may be underestimated.

Abbreviations
5-FU: 5-fluorouracil; AC: Adenocarcinoma; AUC: Area under the curve; CBP: Carboplatin; CCR: Concurrent chemoradiotherapy; CR: Complete response; CT: Computed tomography; CTV: Clinical target volume; DDP: Cisplatin; EC: Esophageal carcinoma; ESCC: Esophageal squamous cell carcinoma; GTV: Gross tumor volume; MDACC: University of Texas M.D. Anderson Cancer Center; OS: Overall survival; pCR: Pathologic complete response; PF: Cisplatin combined with 5-fluorouracil continuous infusion; PTV: Planning target volume; PTX: Paclitaxel; RTOG: Radiation therapy oncology group; SC: Squamous cell carcinoma; TF: Paclitaxel plus 5-fluorouracil; TP: Paclitaxel plus cisplatin; TPF: Paclitaxel plus cisplatin plus 5-fluorouracil

Acknowledgements
Not applicable.

Funding
The ESO-Shanghai 1 trial is supported by the National Natural Science Foundation of China Research, China (grant 21172043).

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study until now.

Authors’ contributions
KZ and YC planned the study. YC, KZ, ZZ, WZ, LL, JY, CW, HT, QL, JL, YX, YL, and JZ are conducting the study. KZ and YC are responsible for the patient recruitment. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The final protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (1203108–4).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no financial or non-financial competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 DongAn Road, Shanghai 200032, China. 2 Jiangsu Cancer Hospital, Nanjing, China. 3 Zhejiang First People’s Hospital, Zhejiang, China. 4 The First Affiliated Hospital of Xiamen University, Xiamen, China. 5 Fujian Provincial Cancer Hospital, Fuzhou, China. 6 Fudan University Shanghai Cancer Center Minhang Branch, Shanghai, China. 7 Affiliated Hospital of JiaNan University, WuXi, China.

Received: 14 April 2017 Accepted: 16 February 2018
Published online: 27 February 2018

References
1. Cooper JS, Guo MD, Henskovic A, MacDonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitlet JJ, Spencer S, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA. 1999;281(17):1623–7.
2. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86(14):1086–91.
3. Ilson DH, Wadleigh RS, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007;18(5):898–902.
4. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999;9(Suppl. 1):12–26.
5. Tischler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992;22(3):613–7.
6. van Rijn J, van den Berg J, Meijer DW. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int J Radiat Oncol Biol Phys. 1995;33(3):635–9.
7. Milas L, Hunter N, Mason KA, Milross C, Peters LJ. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radiosensitivity. Acta Oncol. 1995;34(3):409–12.
8. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1995;55(16):3564–8.

9. Kelsey CR, Chino JP, Willett CG, Clough RW, Hurwitz HI, Morse MA, Bendell JC, D’Amico TA, Czito BG. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys. 2007;69(3):770–6.

10. Weiner LM, Colarusso P, Goldberg M, Dresler C, Coia LR. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before seminorad. Semin Oncol. 1997;24(6 Suppl 19):519–530.

11. Wright CD, Wain JC, Lynch TJ, Choi NC, Grossbard ML, Carey RW, Moncure AC, Grillo HC, Mathieu DJ. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg. 1997;114(5):811–5. Discussion 816

12. Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA, Zuccaro G. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18(9):2032–9.

13. Thirion P, Piedbois Y. Preoperative chemoradiotherapy using taxanes for locally advanced esophageal carcinoma. J Clin Oncol. 2001;19(9):1880–2.

14. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornbuck D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26(28):4551–6.

15. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Kelsen DP, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2000;18(5):1567–74.

16. Van Meter EM, Garrett-Mayer E, Bandypadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clinical trials. 2012(3):303–13.

17. CHEN Y, Ai T, Xia Y, Liu Q, Zhang J, Zhao K. Results of a phase II study of concurrent S-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus. Chin Oncol. 2016;26(11):926–31.

18. Henkovic A, Martz K, al-Sarraf M, Hayman JA, Thomas M, Sutton VM, Davis JL, Kalman LA, Shaffer DW, Yost K, Rinaldi DA, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional S-FLU and radiation therapy in locoregional esophageal cancer: final results of a Minnie pearl cancer research network phase II trial. Cancer J. 2003;9(4):251–60.

19. Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL, Lee YC. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol. 2007;18(1):93–8.

20. Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF Jr, Fitch TR, Alberts SR, et al. Paclitaxel, carboplatin, S-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: northern central cancer treatment group (N0044). Am J Clin Oncol. 2007;30(5):507–13.

21. Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, Choi NC. Concurrent cisplatin, S-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1120–8.